Please ensure Javascript is enabled for purposes of website accessibility

Why Corbus Pharmaceuticals Is Getting Slammed Today

By George Budwell – Sep 8, 2020 at 9:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A late-stage clinical failure is weighing heavily on the biotech's stock today.

What happened

Shares of the clinical-stage biotech Corbus Pharmaceuticals Holdings (CRBP -6.38%) fell by as much as 77% in pre-market trading Tuesday morning. The drugmaker's shares are tanking this morning in response to a negative late-stage readout for lenabasum in patients with a rare autoimmune disorder known as diffuse cutaneous systemic sclerosis (SSc).

Lenabasum, an oral synthetic endocannabinoid-mimetic that selectively binds to the cannabinoid receptor type 2, reportedly failed to outperform placebo on the trial's primary and secondary endpoints. The drug's other ongoing trials for dermatomyositis, systemic lupus erythematosus, and cystic fibrosis are unaffected by this late-stage miss, according to the company's press release.

A man getting punched in the face.

Image source: Getty Images.

So what

Lenabasum stood to become the first ever FDA-approved treatment for SSc. Corbus, in turn, would have more than likely had a blockbuster drug on its hands if the drug had passed this critical test. So, given the potential financial impact of this late-stage clinical failure on Corbus' future revenue, it's easy to see why shareholders are heading for the exits today.  

Now what

Should bargain hunters pounce on this biotech stock today? Lenabasum may ultimately redeem itself in another high-value indication. Corbus, after all, isn't that far off from releasing the drug's top-line results in cystic fibrosis. That's the good news. 

The bad news is that there's no reliable way to handicap the outcome of any clinical trial. So, unless you have an exceedingly high tolerance for risk and volatility, it's probably best to stick to the sidelines with this name for now. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Corbus Pharmaceuticals Holdings, Inc. Stock Quote
Corbus Pharmaceuticals Holdings, Inc.
$0.16 (-6.38%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.